

Pei-yu Huang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9706713/publications.pdf>

Version: 2024-02-01

36
papers

2,748
citations

361413

20
h-index

330143

37
g-index

37
all docs

37
docs citations

37
times ranked

2587
citing authors

#	ARTICLE	IF	CITATIONS
1	Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. <i>Lancet Oncology</i> , The, 2015, 16, 645-655.	10.7	593
2	Concurrent Chemoradiotherapy vs Radiotherapy Alone in Stage II Nasopharyngeal Carcinoma: Phase III Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1761-1770.	6.3	286
3	Establishment and Validation of Prognostic Nomograms for Endemic Nasopharyngeal Carcinoma. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv291.	6.3	281
4	Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial. <i>European Journal of Cancer</i> , 2017, 75, 14-23.	2.8	226
5	Prospective Study of Tailoring Whole-Body Dual-Modality [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography With Plasma Epstein-Barr Virus DNA for Detecting Distant Metastasis in Endemic Nasopharyngeal Carcinoma at Initial Staging. <i>Journal of Clinical Oncology</i> , 2013, 31, 2861-2869.	1.6	171
6	Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. <i>European Journal of Cancer</i> , 2019, 119, 87-96.	2.8	150
7	Phase III Study Comparing Standard Radiotherapy With or Without Weekly Oxaliplatin in Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: Preliminary Results. <i>Journal of Clinical Oncology</i> , 2005, 23, 8461-8468.	1.6	147
8	Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma. <i>JAMA Oncology</i> , 2020, 6, 1345.	7.1	137
9	A new prognostic histopathologic classification of nasopharyngeal carcinoma. <i>Chinese Journal of Cancer</i> , 2016, 35, 41.	4.9	83
10	Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma. <i>Oncotarget</i> , 2016, 7, 13060-13068.	1.8	80
11	A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2012, 48, 1038-1044.	1.5	65
12	Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study. <i>Chinese Journal of Cancer</i> , 2016, 35, 2.	4.9	62
13	Pretreatment body mass index as an independent prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy: Findings from a randomised trial. <i>European Journal of Cancer</i> , 2013, 49, 1923-1931.	2.8	58
14	Elevated peripheral blood lymphocyte-to-monocyte ratio predicts a favorable prognosis in the patients with metastatic nasopharyngeal carcinoma. <i>Chinese Journal of Cancer</i> , 2015, 34, 237-46.	4.9	44
15	Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area. <i>European Journal of Cancer</i> , 2015, 51, 1760-1770.	2.8	43
16	Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	37
17	Is Hemoglobin Level in Patients with Nasopharyngeal Carcinoma Still a Significant Prognostic Factor in the Era of Intensity-Modulated Radiotherapy Technology?. <i>PLoS ONE</i> , 2015, 10, e0136033.	2.5	28
18	Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy. <i>Oral Oncology</i> , 2012, 48, 964-968.	1.5	27

#	ARTICLE	IF	CITATIONS
19	Multi-institutional prospective study of nedaplatin plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 68-74.	3.2	24
20	The role of the bacterial microbiome in the treatment of cancer. <i>BMC Cancer</i> , 2021, 21, 934.	2.6	22
21	Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma. <i>JAMA Oncology</i> , 2022, 8, 706.	7.1	22
22	The impact of the cumulative dose of cisplatin during concurrent chemoradiotherapy on the clinical outcomes of patients with advanced-stage nasopharyngeal carcinoma in an era of intensity-modulated radiotherapy. <i>BMC Cancer</i> , 2015, 15, 977.	2.6	21
23	A curative-intent endoscopic surgery for postradiation nasopharyngeal necrosis in patients with nasopharyngeal carcinoma. <i>Cancer Communications</i> , 2018, 38, 1-11.	9.2	21
24	Expression of EIF5A2 associates with poor survival of nasopharyngeal carcinoma patients treated with induction chemotherapy. <i>BMC Cancer</i> , 2016, 16, 669.	2.6	17
25	The impact of smoking on the clinical outcome of locoregionally advanced nasopharyngeal carcinoma after chemoradiotherapy. <i>Radiation Oncology</i> , 2014, 9, 246.	2.7	15
26	Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥ 4000 copies/ml: a matched study. <i>Oncotarget</i> , 2016, 7, 29739-29748.	1.8	15
27	A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4186-4194.	7.0	15
28	Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinoma. <i>Chinese Journal of Cancer</i> , 2015, 34, 177-83.	4.9	10
29	C-KIT overexpression and mutation in nasopharyngeal carcinoma cell lines and reactivity of Imatinib on these cell lines. <i>Chinese Journal of Cancer</i> , 2010, 29, 131-135.	4.9	9
30	Paired study of 172 cases of nasopharyngeal carcinoma with or without dermatomyositis. <i>Acta Oto-Laryngologica</i> , 2014, 134, 824-830.	0.9	8
31	Prognostic significance of the various classifications for parapharyngeal space involvement in nasopharyngeal carcinoma. <i>Acta Oto-Laryngologica</i> , 2012, 132, 1197-1207.	0.9	6
32	Association between Pretreatment Serum High-density Lipoprotein Cholesterol and Treatment Outcomes in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma Treated with Chemoradiotherapy: Findings from a Randomised Trial. <i>Journal of Cancer</i> , 2019, 10, 3618-3623.	2.5	4
33	Metastatic characteristics associated with survival of synchronous metastatic nasopharyngeal carcinoma in non-epidemic areas. <i>Oral Oncology</i> , 2021, 115, 105200.	1.5	4
34	The impact of induction chemotherapy on long-term quality of life in patients with locoregionally advanced nasopharyngeal carcinoma: Outcomes from a randomised phase 3 trial. <i>Oral Oncology</i> , 2021, 121, 105494.	1.5	4
35	Efficacy of local therapy to metastatic foci in nasopharyngeal carcinoma: large-cohort strictly-matched retrospective study. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211124.	3.2	4
36	Proteomic Analysis of a Nasopharyngeal Carcinoma Cell Line and a Nasopharyngeal Epithelial Cell Line. <i>Tumori</i> , 2015, 101, 676-683.	1.1	3